Who are Rasagiline mesylate with Levodopa's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rasagiline-mesylate-with-levodopa.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Rasagiline mesylate with Levodopa — Competitive Intelligence Brief

Rasagiline mesylate with Levodopa (Rasagiline mesylate with Levodopa) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: MAO-B inhibitor combined with dopamine precursor. Area: Neurology.

marketed MAO-B inhibitor combined with dopamine precursor Monoamine oxidase B (MAO-B); Dopamine pathway Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Rasagiline mesylate with Levodopa (Rasagiline mesylate with Levodopa) — Teva Neuroscience, Inc.. Rasagiline is a monoamine oxidase B (MAO-B) inhibitor that increases dopamine levels in the brain, while levodopa is converted to dopamine to replace depleted neurotransmitter in Parkinson's disease.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Rasagiline mesylate with Levodopa TARGET	Rasagiline mesylate with Levodopa	Teva Neuroscience, Inc.	marketed	MAO-B inhibitor combined with dopamine precursor	Monoamine oxidase B (MAO-B); Dopamine pathway

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (MAO-B inhibitor combined with dopamine precursor class)

Teva Neuroscience, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Rasagiline mesylate with Levodopa — Competitive Intelligence Brief. https://druglandscape.com/ci/rasagiline-mesylate-with-levodopa. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab